

Rapid Automated Large Structural Variation Detection in a Diploid Genome by NanoChannel Based Next-Generation Mapping

Alex R Hastie^{1*}, Ernest T Lam^{1*}, Andy Wing Chun Pang^{1*}, Luna Xinyue Zhang¹, Warren Andrews¹, Joyce Lee¹, Tiffany Y Liang¹, Jian Wang¹, Xiang Zhou¹, Zhanyang Zhu¹, Thomas Anantharaman¹, Željko Džakula¹, Sven Bocklandt¹, Urvashi Surti², Michael Saghbini¹, Michael D. Austin¹, Mark Borodkin¹, R. Erik Holmlin¹, Han Cao^{1‡}

¹Bionano Genomics, San Diego, CA

²University of Pittsburg, Pittsburg, PA

* Authors contributed equally

‡ Correspondence should be addressed to: han@bionanogenomics.com

The human genome is diploid with one haploid genome inherited from the maternal and one from the paternal lineage. Within each haploid genome, large structural variants such as deletions, duplications, inversions, and translocations are extensively present and many are known to affect biological functions and cause disease. The ultimate goal is to resolve these large complex structural variants (SVs) and place them in the correct haploid genome with correct location, orientation, and copy number. Current methods such as karyotyping, chromosomal microarray (CMA), PCR-based tests, and next-generation sequencing fail to reach this goal either due to limited resolution, low throughput, or short read length.

Bionano Genomics' next-generation mapping (NGM) offers a high-throughput, genome-wide method able to detect SVs of one kilobase pairs (kbp) and up. By imaging extremely long genomic molecules of up to megabases in size, the structure and copy number of complex regions of the genome including interspersed and long tandem repeats can be elucidated in their native form without inference.

Here we tested Bionano's SV high sensitivity discovery algorithm, Bionano Solve 3.0, on *in silico* generated diploid genomes with artificially incorporated SVs based on the reference genome, hg19, achieving over 90% overall detection sensitivity for heterozygous SVs larger than 1 kbp. Next, in order to benchmark large SV detection sensitivity and accuracy on real biological data, we used Bionano NGM to map two naturally occurring hydatidiform mole cell lines, CHM1 and CHM13, each containing a different duplicated haploid genome. By *de novo* assembling each of two mole's genome separately followed by assembling a mixture of CHM1 and CHM13 data, we were able to call 2156 unique SVs (> 1.5 kbp) in each haploid mole and a simulated diploid. By comparing the simulated diploid SV calls against the SV calls in each single haploid mole assembly we established 87.4% sensitivity for detection of heterozygous SVs and 99.2%

sensitivity for homozygous SVs. In comparison, a recent SV study on the same CHM1/CHM13 samples using long read NGS alone showed 54% sensitivity for detection of heterozygous SVs and 77.9% for homozygous SVs larger than 1.5 kbp. We also compared an SV call set of the diploid cell line NA12878 with the results of an earlier mapping study (Mak AC, 2016) and found concordance with 89% of the detected SVs found in the previous study and, in addition, 2599 novel SVs were detected. Finally, two pathogenic SVs were found in cell lines from individuals with developmental disorders. *De novo* comprehensive SV discovery by Bionano NGM is shown to be a fast, inexpensive and robust method, now with an automated informatics workflow.

Introduction

The importance of understanding the role of large SVs in genetic disorders cannot be overstated. For many known syndromes, clinically relevant large SVs are well characterized: deletions have been found to cause Prader-Willi syndrome, DiGeorge syndrome, and Williams-Beuren syndrome; duplications can cause Charcot-Marie-Tooth disease, and inversions can cause haemophilia A (Emanuel BS, 2001). More recently, large SVs have been found to play a role in neurological disease, such as early-onset neuropsychiatric disorders (Brand H, 2014), Tourette syndrome (Fernandez TV, 2012), and Parkinson's disease (Butcher NJ, 2013); and in coronary heart disease (Crawford DC, 2008) and congenital heart disease (Bittel DC, 2014). SVs have also been shown to influence obesity (Bochukova EG, 2010) and pharmacogenetics (Rasmussen HB, 2012).

Cancer cells typically show extreme rearrangements of the genome. SVs are found in most cancer types. Examples are FGFR3-IGH fusion genes in multiple myeloma caused by a translocation and deletion, or the Philadelphia chromosome found in chronic myeloid leukemia (Krem MM, 2015).

Existing technologies including chromosomal microarrays and whole genome sequencing diagnose fewer than 50% of patients with suspected genetic conditions (Miller DT, 2010) (Lee H, 2014). This leaves a majority of patients without ever receiving a molecular diagnosis. Chromosomal microarray lacks the ability to detect structural variants in which no loss or gain of sequence took place. Balanced translocations and inversions are essentially invisible to these technologies.

Clinical exome sequencing solves about 30% of rare diseases (Lee H, 2014). NGS reliably identifies single nucleotide variants and small insertions and deletions. It relies on short-read sequences that are mapped to a reference human genome and has limited power to identify most larger insertions, deletions, and copy-number variations. Various NGS based SV calling algorithms routinely disagree with each other and have limited power to detect SVs such as inversions and translocations (Alkan C, 2011). Huddleston *et al.* used long read technology by Pacific Biosciences to call structural variants in cell lines that were extensively analyzed using short-read sequencing as part of the 1000 Genomes Project. They report that > 89% of the variants identified using long reads have been missed as part of the analysis of the 1000 Genomes Project, even after adjusting for more common variants (Huddleston, 2016).

The true extent of structural variation of the genome has been enigmatic as many types of structural variation are refractory to current technologies. Estimates suggest that structurally variable regions cover 13% of the human genome, and individuals show structural variation covering as much as 30 Mbp between each other (Sudmant PH, 2016). This makes large structural variation the biggest source of individual genomic variation (Pang, 2010). In addition, the human genome is diploid with one of each haploid genome inherited from the maternal and the paternal lineage. Phenotypical or pathological outcomes are results of interplay between variants of the two haploid genomes. In order to understand genetic diseases and develop treatments and diagnostic tools for them, it is important to be able to identify these SVs and determine which variant belongs to which haploid genome. To completely resolve these large complex structural variants such as balanced chromosomal lesions and interspersed repeats and place them in their appropriate haploid with correct location, orientation and copy number has been the ultimate goal in genomic research and precision diagnostics. Current methods such as karyotyping, chromosomal microarray (CMA), PCR-based tests, and next-generation sequencing fail to reach this goal, either due to their limited resolution, low throughput, or short read length.

Bionano Genomics' Next-Generation Mapping (NGM) can elucidate all SV types, larger than 1 kbp. Extremely long (hundreds of kilobases to multiple megabases) genomic DNA is extracted from the sample source and fluorescently labeled at nicking endonuclease recognition sites consisting of specific 6-7 bp sequences, after which it is linearized and uniformly stretched in high density NanoChannel arrays, and imaged on the Irys System (Lam et al.,). Since the molecules are linear and uniformly stretched, the distances between labels can be accurately measured, resulting in single molecule maps with a unique labeling pattern ("barcode") which has a density of approximately 10 times per 100 kbp on average (for human genomes). Using an overlap-layout-consensus assembly algorithm, consensus genome maps are constructed, refined, extended, and merged to create a *de novo* diploid genome map assembly useful for heterozygous SV detection. Multiple genome map assemblies can be created, each using a different endonuclease, and may be scaffolded together along with the reference sequence to generate broader coverage and higher label density.

Bionano maps are built completely *de novo*, based on specific nick-labeling patterns on native long intact molecules, without any reference guidance. This differentiates NGM from NGS, or inferred synthetic long reads, where short-read sequences are typically aligned to a reference and reconstructed. When short reads are forced to align to a potentially incorrect, incomplete or divergent reference, or when mismatched reads are excluded from the alignment, SVs in the region may be missed or mischaracterized. More importantly, short-read based technologies are less likely to readily detect novel insertions, mobile element insertions, variable number tandem repeat variants or balanced SVs such as inversions and translocations such as those that cause certain diseases. *De novo* constructed individual genomes using Bionano maps allow for comprehensive structural variation analysis.

Results

We report the use of a fully automated SV calling pipeline for Bionano NGM to identify large (> 1 kbp) homozygous and heterozygous SVs with unprecedented sensitivity and specificity.

To benchmark large SV detection sensitivity and accuracy in a diploid genome, we first generated an *in silico* map of the human reference genome, hg19, and incorporated random SVs to create an *in silico* diploid genome. We used this to test Bionano's sensitivity and specificity to detect insertions, deletions, and translocations against the *in silico* "ground truth."

Next, we used Bionano NGM to map two naturally occurring hydatidiform mole cell lines, CHM1 and CHM13, each containing a different duplicated haploid genome. By *de novo* assembling each of two mole genomes separately, followed by assembling a mixture of CHM1 and CHM13 molecules, we were able to compare the simulated diploid, heterozygous SV calls against the homozygous SV calls in each single haploid mole assembly.

We further tested this new pipeline in a well characterized diploid cell line NA12878, which was previously mapped with Bionano Irys technology and heavily manually curated (Mak AC, 2016). The improved SV detection sensitivity improved by more than fourfold, primarily by improving sensitivity for insertions and deletions down to 1 kbp from the 5 kbp threshold set in the previous study. Finally, the Bionano SV workflow was applied to cell lines containing known translocations, GM16736 and GM21891.

***In silico* insertion, deletion, and translocation sensitivity estimates**

A total of 1600 insertions and 1600 deletions were randomly introduced into an *in silico* map of the human reference genome, hg19, such that SVs ranged from 200 bp to 1 Mbp, SVs were separated by at least 500 kbp, and each SV was heterozygous. Based on the edited and the unedited hg19, molecules were simulated to resemble actual molecules collected by Bionano NGM technology. Two sets of molecules were simulated, each based on a different nicking endonuclease. Simulated molecule datasets, with 70x effective coverage, were generated and assembled and used as input for the Bionano Solve 3.0 pipeline. SV calls were made by combining the data from both nick motifs such that matching SV calls from two enzymes were merged into a single call. The final merged SV calls were compared to the *in silico* ground truth SV call set.

Figure 1 shows sensitivity and positive predicted value (PPV) for heterozygous insertions and deletions within a large size range. SVs calls were generated independently for each of the two nicking enzymes, and sensitivity and PPV are plotted for each as well as a combined SV set (SVMerge), which is a result of combining unique SVs from each enzyme and collapsing SVs called by each enzyme (merged SVs also have higher confidence as they are called independently twice). Overall sensitivity for heterozygous SVs larger than 1 kbp was 90.2% for SVMerged SVs. Insertion and deletion size

measurements have only a 49 bp median error, while reported breakpoints were a median distance of 3.3 kbp from the actual breakpoint coordinates. Breakpoint resolution is limited by the density of nick motif (every 5 kb on average when both Nt.BspQI and Nb.BssSI enzymes are used). Some large insertions (> 200 kbp) were found but classified as “end” calls when only one of both breakpoints was present in a single genome map.




Figure 1: Heterozygous SV calling performance from a simulated dataset. Molecules were simulated from unedited and edited versions of hg19 (with insertions and deletions of different sizes) and used for assembly and SV calling. SV detection sensitivity and PPV across different size ranges are shown based on assemblies from molecules labeled with nicking endonuclease Nt.BspQI, Nb.BssSI, and combined data from both motifs (SVMerge).

Translocations were simulated similarly to insertions and deletions. Sensitivity for heterozygous translocations was shown to be 98% for breakpoint detection. Because NGM has relatively high precision relative to cytogenetic assays, many breakpoints are defined to within a few kbp of the precise breakpoint, and this distance is often close enough for PCR validation of translocations discovered by NGM. Genome mapping can define the true positions of breakpoints within a median distance of 2.9 kbp.

Homozygous and heterozygous SVs in a simulated diploid based on CHM1 and CHM13 double haploid cell lines

Since there is no structurally accurate haploid resolved genome sequence available from a natural diploid human sample that can be used as the ground truth to evaluate a technology and algorithm for sensitivity in detecting SVs, a diploid human genome was simulated by combining data from two haploid hydatidiform mole derived cell lines, as done by Huddleston *et al.* These moles usually occur when an oocyte without nuclear

DNA gets fertilized by a sperm. The haploid genome in the sperm is duplicated, and the cell line resulting from this tissue (such as CHM1 and CHM13) is therefore expected to be entirely homozygous.

Genomic DNA from CHM1 and CHM13 was isolated, labeled at Nt.BspQI nick sites and at Nb.BssSI nick sites in separate reactions, and mapped using the Irys instrument. Molecules imaged in each cell line were *de novo* assembled using the Bionano Solve 3.0 pipeline. SVs detected in the homozygous cell lines were considered the (conditional) ground truth. An equal mixture of randomly selected single molecule data from the two cell lines was assembled to simulate a diploid genome, and SV calls made from this mixture were used to estimate the pipeline's sensitivity to detect homozygous and heterozygous SVs. Assembly statistics are shown in Table 1.

Sample	CHM1		CHM13		Mixture	
	Nt.BspQI	Nb.BssSI	Nt.BspQI	Nb.BssSI	Nt.BspQI	Nb.BssSI
Data collected (Gbp) for molecules >150 kbp	251.32	219.08	315.78	341.30	374.90	344.54
Molecules N50 (kbp)	277.99	239.63	308.60	289.79	292.60	246.46
Assembly size (Gbp)	2.90	2.89	2.90	2.87	5.63	5.76
Genome map N50 (Mbp)	7.07	2.61	4.48	2.18	7.10	3.00

Table 1: Metrics for assemblies from data from CHM1, CHM13, and an equal mixture of both. Samples were labeled at Nt.BspQI and at Nb.BssSI nick sites in separate reactions.

Table 2 shows the number of insertions and deletions larger than 1.5 kbp detected in the CHM1 and CHM13 homozygous cell lines, and the *in silico* CHM1/13 mixture. SVs detected in CHM1 only or CHM13 only are considered heterozygous and those detected in both are homozygous. Overall, NGM has detected a total of 2156 SVs larger than 1.5 kbp from CHM1 and CHM13, with 1370 insertions and 786 deletions. When the simulated diploid was used as the input data, the NGM SV pipeline detected 1999 SVs: 1254 insertions and 745 deletions. This method has an overall detection sensitivity of 92.7%, with 91.5% sensitivity and 97.9% PPV (Positive Predictive Value) for insertions, and 94.8% sensitivity and 97.1% PPV for deletions. It detected 976 homozygous and 1180 heterozygous SVs from the two haploid samples and 968 homozygous and 1031 heterozygous SVs from the simulated diploid. In this case, it has a 99.2% sensitivity for homozygous calls and 87.4% sensitivity for heterozygous calls.

	PACBIO				BIONANO			
	CHM1 and CHM13 assemblies	Mixture assembly	Sensitivity	PPV	CHM1 and CHM13 assemblies	Mixture assembly	Sensitivity	PPV
Homozygous Insertions	467	353	75.6%	96.1%	707	700	99.0%	97.9%
Heterozygous Insertions	586	252	43.0%		663	554	83.6%	
Homozygous Deletions	221	183	82.8%	94.9%	269	268	99.6%	97.1%
Heterozygous Deletions	501	337	67.3%		517	477	92.3%	

Table 2: Two homozygous cell lines, CHM1 and CHM13 were independently *de novo* assembled and insertions and deletions >1.5 kbp were called. Raw data from both cell lines were combined and assembled, and SVs were called on the new assembly (mixture assemblies column). The sensitivity and specificity (PPV) to detect heterozygous relative to homozygous SVs is shown.

A similar experiment using PacBio long-read sequencing was described recently (Huddleston, 2016). Structural variants in CHM1 and CHM13 were called separately with the SMRT-SV algorithm, and compared to those called using an equal mixture of reads of both haplotypes at 60x combined coverage depth.

The reported total number of SVs larger than 1.5 kbp detected by PacBio sequencing was 1775 from CHM1 and CHM13, with 1053 insertions and 722 deletions. When the simulated diploid was used as the input data, the reported total number of SVs was 1125, with 605 insertions and 520 deletions. This method has an overall detection sensitivity of 63.4%, with 57.5% sensitivity and 96.1% PPV for insertions, and 72.0% sensitivity and 94.9% PPV for deletions. The pipeline reported 688 homozygous and 1087 heterozygous SVs from two haploid samples, and 536 homozygous and 589 heterozygous SVs from the simulated diploid.

SV performance compared to other benchmark experiments in diploid cells

Mak et al., mapped genome wide structural variation using NGM in the CEPH trio, (NA12878, NA12891, NA12892) using automated and manual bioinformatics approaches. They found 7 times more large SVs (longer than 5 kbp) than previous studies based on high-depth Illumina short reads (1000 Genomes Project Consortium et al. 2010, 2012). We used our current fully automated approach to compare with that benchmark study, and found 89% of their reported SVs while also finding fourfold as many total SVs, as a result of improved sensitivity with the new assembly and SV algorithms. We have also benchmarked NGM SV calling with PacBio SV calling as reported by Chaisson et al. for CHM1. Based on this comparison; we show that NGM can detect 73% of SVs called by PacBio while calling an additional 20% more SVs. PacBio sequencing captures only 47% of Bionano SVs. SV call sizes have a median deviation between Bionano and PacBio (Figure 2C) based calls of 91 bp, which is larger than the 49 bp median error found in the *in silico* simulation, but still represents very good concordance. The increased deviation was likely caused, at least partially, by compounded error from making two empirical measurements compared to having a ground truth as in the *in silico* test.




Figure 2: A. Comparison of SVs detected by Mak et al through automated and manual curation and those detected with the automated Bionano Solve 3.0 pipeline. B. Comparison of SVs detected through PacBio sequencing and SMRT-SV and those detected by Bionano Solve 3.0 for CHM1. C. Plot of the size of overlapping SVs from B.

In addition, translocation detection sensitivity was verified in two reference samples, NA16736 and NA21891, which are lymphoblast cell lines produced from blood cells from a patient with a developmental disorders resulting in deafness with DNA repair deficiency caused by t(9;22) translocation, and a second patient with Prader-Willi syndrome associated with a t(4;15) translocation, both of which have been characterized by traditional cytogenetic methods. NGM was able to detect both expected translocations as well as the reciprocal translocation breakpoints. Additionally, NA16736 contained a t(12:12) rearrangement which flanked an inverted segmental duplication. In NA21891, one translocation breakpoint could be localized within a gene, resulting in a predicted truncation (Figure 3).

Reciprocal Translocation Breakpoints in an Individual with Prader-Willi syndrome




Figure 3: Example of a translocation detected by NGM, associated with Prader-Willi syndrome. Blue bars are Bionano maps, and vertical lines represent Nt.BspQI label sites. For each of the reciprocal translocation breakpoints, maps are shown with alignments of the maps to chromosome 4 (top) and chromosome 15 (bottom) of the human reference hg19. Breakpoint resolution can be determined by the distance between matched and unmatched labels.

Discussion

We have tested Bionano Genomics's NGM platform and new algorithm pipelines for sensitivity and accuracy of detection of large SVs (> 1 kbp) of *in silico* diploid genomes, as well as with several human cell lines with known structural features.

The *in silico* created diploid genome based on hg19 and an edited version of the same maps incorporating simulated SVs were used to test the SV calling capability for heterozygous variants. The artificial insertions and deletions were random sets of all sizes, mimicking empirical data, although the perfect 50:50 mixing of two artificial haploid does not always reflect the true nature of biological samples.

We found excellent overall sensitivity of over 90% for insertions and deletions > 1 kbp. We tested sensitivity for insertions and deletions from 200 bp to 1 Mbp. We have not focused on small events, as these are well addressed by NGS, especially long read sequencing.

We similarly simulated thousands of translocations and found an overall sensitivity of 98% to detect the translocation breakpoints. We correctly identified translocations and

the reciprocal breakpoints in two cell lines with known translocations. Compared to traditional cytogenetics, NGM has high resolution of SV breakpoints, resulting in 2.9 kbp median accuracy for breakpoint resolution, often sufficient for PCR and sequencing if single nucleotide resolution of the fusion point is desired for subsequent gene function study.

By *de novo* assembling each of two hydatidiform moles genome (CHM1 and CHM13) separately followed by assembling a mixture of CHM1/13 molecules, we were able to compare the simulated diploid SV calls against the SV calls in each single haploid assembly. Here again, the sensitivity to detect insertions and deletions > 1.5 kbp was 87.4% for heterozygous and 99.2% for homozygous variants. This far exceeds the sensitivity reported for other technologies for insertions, deletions, and translocations above 1 kbp (Huddleston J, 2016).

In a detailed comparison, Bionano had 381 (21.5%) more SV calls than the PacBio based study in the haploid cell lines, and 874 (77.7%) more SV calls in the diploid genome. The sensitivity to detect homozygous SVs > 1.5 kbp in the simulated diploid experiment using PacBio was 77.9%, compared to 99.2% for Bionano. In the case of heterozygous SV calls, which is more challenging for any technology and method, the sensitivity to detect heterozygous SVs > 1.5 kbp using PacBio was 54.0%, compared to 87.4% sensitivity for Bionano. Furthermore, PacBio has only 43.0% sensitivity for heterozygous insertions and 67.3% for heterozygous deletions larger than 1.5 kbp, while notably, Bionano NGM has a much higher 83.6% detection sensitivity for heterozygous insertions and 92.3% for heterozygous deletions larger than 1.5 kbp.

We have further tested this new pipeline in a well characterized diploid cell line NA12878, which was previously mapped with Bionano Irys technology. Our new SV calling pipeline improved significantly on the published work by fully automating the detection of insertions and deletions, and by greatly improving sensitivity partially by expanding the size range of the variants down to 1 kbp from the published 5 kbp.

All current methodologies for detecting SVs have significant limitations. Chromosomal microarray has good performance for large duplications and deletions but is insensitive to novel insertions, mobile element insertions, many low copy repeats, and all balanced translocations and inversions. Short read based methods have poor sensitivity to most large variants. Long read sequencing performs well for homozygous SVs up to around their read lengths but has relatively low sensitivity for heterozygous SVs, including smaller ones and those involving larger repetitive regions.

Precision medicine starts with a precision genome, yet obtaining complete and accurate genomic structural variation information efficiently and inexpensively remains the biggest challenge for the genomic and medical community. Bionano Genomics' NGM is currently the most cost-effective, relatively fast, and accurate technology able to detect a wide spectrum of SV types – balanced and unbalanced, simple and complex, spanning a wide size range from 1 kbp to megabases. The sensitivity to detect heterozygous SVs reported here is superior to other methodologies for a broad range of SV types. Furthermore, NGM has a resolution that is orders of magnitude better than karyotyping and FISH. Bionano Next Generation Mapping is an essential tool for generating a

complete picture of the structure of genomes, paving the way to realizing the full potential of applying genomic information towards translational research and clinical diagnostics and therapeutics.

Materials and methods

Improvements to assembly and analysis pipeline We introduced a number of improvements to the Bionano Solve 3.0 assembly and analysis pipeline:

Assembly: Bionano Solve 3.0 enables improved insertion, deletion, and translocation detection. While the basic strategy of overlap-layout-consensus assembly remains the same, new haplotype-aware assembly components were implemented to more effectively accommodate large heterozygous variants.

During extension stages of assembly, by analyzing molecule-to-genome map alignments, clusters of molecules with coordinated disrupted alignment are split and separately assembled. Molecules from different alleles are “peeled off”; therefore, it is possible to handle more than two alleles. This new component is critical for assembly of haplotype maps with large differences, and for detection of variants across a wide size range. It improves assembly of segmental duplication regions, where large stretches of sequence appear more than once in the genome.

SVMerge:

SVMerge for insertions, deletions, and translocations allows users to take advantage of having two single-enzyme datasets (for example, Nt.BspQI and Nb.BssSI). SVMerge provides several potential benefits. The complementary nature of the two enzymes helps improve sensitivity compared to one-enzyme detection. Cross-confirmation by two independent assemblies provides a useful means of validating variant calls. We expect improved SV breakpoint accuracy due to higher combined labeling site density. For insertions and deletions, SV size estimates are expected to be more accurate for the same reason. Confidence scores for insertions and deletions reflect whether just one or both enzymes support an SV call.

Briefly, SVMerge examines SV calls from single-enzyme assemblies and evaluates whether they are overlapping calls. Overlapping calls are then merged, and refined breakpoint coordinates are output.

Construction of simulated diploid genomes

SVs are detected based on analysis of a multiple local alignment between genome maps and the reference. Translocation breakpoints are detected as fusion points between supposedly distant regions of the genome. Intrachromosomal translocation breakpoints involve regions at least 5 Mbp apart. Interchromosomal translocation breakpoints by definition involve regions on different chromosomes.

We simulated random SV events so that we could estimate our genome-wide SV calling performance accurately. The human reference assembly hg19 was used as an “SV-free” base genome. Random translocation events were simulated to form an edited genome. Two types of translocation events were simulated:

In simulated “cut-and-paste” genomes, up to 1,000 segments were randomly selected across hg19 and randomly inserted elsewhere in the genome. We avoided N-base gaps, and the size of the translocation fragments ranged from 50 kbp to 1 Mbp. Translocation breakpoints were at least 500 kbp away from each other. For simulated intrachromosomal translocations, the breakpoints were at least 5 Mbp apart. For simulated reciprocal translocations, one or two breakpoints were randomly simulated on hg19, and the ends of the chromosomes were reciprocally exchanged between them. In both types of translocations, the genomic material remained the same but with a different arrangement compared to the unmodified hg19. The exchange is balanced, and thus no copy number variation was generated.

Acknowledgments:

Saki Chan, Khoa Pham, Jeff Reifenger, Pui Yan Kwok, Evan Eichler, Carl Baker

Works Cited

1000 Genomes Project Consortium, G. R. (2010). A map of human genome variation from population-scale sequencing. .

1000 Genomes Project Consortium, G. R. (2012). An integrated map of genetic variation from 1,092 human genomes. . *Nature* , 491, 56-65.

Alkan C, S. S. (2011). Limitations of next-generation genome sequence assembly. *Nat Methods* , 8, 61-65.

Bittel DC, Z. X. (2014). Ultra high-resolution gene centric genomic structural analysis of a non-syndromic congenital heart defect, Tetralogy of Fallot. *PLoS One*, 9 (1), e87472.

Bochukova EG, H. N.-S.-S. (2010). Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature*, 463 (7281), 666-70.

Brand H, P. V. (2014). Cryptic and complex chromosomal aberrations in early-onset neuropsychiatric disorders. *Am J Hum Genet.*, 95 (4), 454-61.

Butcher NJ, K. T. (2013). Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. *JAMA Neurol.*, 70 (11), 1359-66.

Chaisson MJ, H. J. (2015). Resolving the complexity of the human genome using single-molecule sequencing. *Nature*, 517 (7536), 608-11.

Crawford DC, P. Z. (2008). LPA and PLG sequence variation and kringle IV-2 copy number in two populations. *Hum Hered.*, 66 (4), 199-209.

de Koning AP, G. W. (2011). Repetitive elements may comprise over two-thirds of the human genome. *PLoS Genet*, 7 (12), e1002384.

Emanuel BS, S. T. (2001). Segmental duplications: an 'expanding' role in genomic instability and disease. *Nat Rev Genet.*, 2 (10), 791-800.

Fernandez TV, S. S.-S. (2012). Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. *Biol Psychiatry*, 71 (5), 392-402.

Huddleston J, C. M.-L. (2016, Nov 28). Discovery and genotyping of structural variation from long-read haploid genome sequence data. *Genome Res*, gr.214007.116.

Krem MM, P. O. (2015). Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. *Br J Haematol*, 171 (1), 13-28.

Lee H, D. J.-R.-A. (2014). Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders. *JAMA*, 312 (18), 1880-1887.

Mak AC, L. Y. (2016). Genome-Wide Structural Variation Detection by Genome Mapping on Nanochannel Arrays. *Genetics*, 202 (1), 351-62.

Miller DT, A. M. (2010). Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet.*, 86 (5), 749-64.

Pang A. W., M. J. (2010). Towards a comprehensive structural variation map of an individual human genome. *Genome Biol*, 11 (R52.10.1186), gb-2010-11-5-r52.

Peter H. Sudmant, T. R.-Y.-W.-B. (2016). An integrated map of structural variation in 2504 human genomes. *Nature* , 526, 75-81.

Rasmussen HB, D. C. (2012). Genome-wide identification of structural variants in genes encoding drug targets: possible implications for individualized drug therapy. *Pharmacogenet Genomics* , 22 (7), 471-83.

Sudmant PH, R. T.-Y.-W.-B. (2016). An integrated map of structural variation in 2504 human genomes. *Nature* , 526, 75-81.